AR113749A1 - Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada - Google Patents

Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada

Info

Publication number
AR113749A1
AR113749A1 ARP180102890A ARP180102890A AR113749A1 AR 113749 A1 AR113749 A1 AR 113749A1 AR P180102890 A ARP180102890 A AR P180102890A AR P180102890 A ARP180102890 A AR P180102890A AR 113749 A1 AR113749 A1 AR 113749A1
Authority
AR
Argentina
Prior art keywords
oral
formulation
synthetic
onset
plant
Prior art date
Application number
ARP180102890A
Other languages
English (en)
Inventor
Gregory Wesner
Andrea Leone-Bay
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of AR113749A1 publication Critical patent/AR113749A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Reivindicación 1: Una formulación oral que comprende (i) un componente de inicio rápido que comprende (a) materia vegetal y/o cannabinoides sintéticos y (b) un aminoácido graso N-acilado o una sal de este; y (ii) un componente de acción continuada que comprende (a) materia vegetal y/o cannabinoides sintéticos y (b) un sistema deliberación sostenida. Reivindicación 80: Un método para preparar una formulación oral de cannabis con un inicio de acción más rápido, donde el método comprende agregar un potenciador de la absorción a la formulación oral de cannabis y donde la formulación oral de cannabis tiene un inicio de acción más rápido que una formulación oral de cannabis sin un potenciador de la absorción. Reivindicación 81: El método de la reivindicación 80, donde el potenciador de la absorción es un aminoácido graso N-acilado o una sal de este.
ARP180102890A 2017-10-05 2018-10-05 Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada AR113749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762568705P 2017-10-05 2017-10-05

Publications (1)

Publication Number Publication Date
AR113749A1 true AR113749A1 (es) 2020-06-10

Family

ID=65992006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102890A AR113749A1 (es) 2017-10-05 2018-10-05 Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada

Country Status (15)

Country Link
US (1) US20200254041A1 (es)
EP (1) EP3672610A4 (es)
JP (1) JP2020536873A (es)
KR (1) KR20200065009A (es)
CN (1) CN111225678A (es)
AR (1) AR113749A1 (es)
AU (1) AU2018345814A1 (es)
BR (1) BR112020006841A2 (es)
CA (1) CA3078549A1 (es)
CL (1) CL2020000909A1 (es)
EA (1) EA202090890A1 (es)
IL (1) IL273366A (es)
MX (1) MX2020003573A (es)
UY (1) UY37920A (es)
WO (1) WO2019071213A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102393596B1 (ko) 2016-04-22 2022-05-04 리셉터 홀딩스, 인크. 속효성 식물-계 의약 화합물 및 영양 보충제
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2020037409A1 (en) * 2018-08-20 2020-02-27 Hexo Operations Inc. Cannabis-infused product with extended cannabinoid profile user experience
AU2020293031B2 (en) 2019-06-12 2022-03-31 Nectar Health Sciences Inc. Methods for extraction, processing, and purification of a selected family of target compounds from cannabis
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
US10780075B1 (en) * 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
US20210275461A1 (en) 2019-09-12 2021-09-09 Nulixir Inc. Particles for administration of active ingredients and methods of making the same
IL292404A (en) * 2019-10-21 2022-06-01 Esolate Ltd Compositions including thin compounds and their production
CA3158289A1 (en) * 2019-11-12 2021-05-20 Mahmoud Mohamed Abdrabo MOUSTAFA Chewing gum containing synergistic medicinal compounds
US20210212950A1 (en) * 2020-01-15 2021-07-15 Resurgent Pharmaceuticals, Inc. Orally deliverable formulation to prevent all cause mortality and cardiovascular events
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
KR102433007B1 (ko) * 2020-07-28 2022-08-16 동의대학교 산학협력단 산골취 추출물을 포함하는 신경병증성 통증 예방 및 개선용 조성물
WO2022115973A1 (en) * 2020-12-04 2022-06-09 Nectar Health Sciences Inc. Solvent-switching methods for precipitation, processing, and purification of selected cannabinoids from concentrated complex mixtures

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) * 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
DE2537232B2 (de) * 1974-08-22 1976-07-01 Spritz- und formmasse
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
EP2292211A3 (en) * 2001-02-14 2014-01-01 GW Pharma Limited Mucoadhesive pharmaceutical formulations
PT1385498E (pt) * 2001-04-18 2007-12-14 Prometic Biosciences Inc Ácidos gordos como factores de sobrevivência e activação de neutrófilos
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1694300A4 (en) * 2003-12-09 2009-04-29 Pharmasset Inc DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
ES2443817T3 (es) * 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12
DK2897620T3 (da) * 2012-09-21 2020-08-17 Intensity Therapeutics Inc Fremgangsmåde til behandling af cancer
WO2015118549A1 (en) * 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
PL3368014T3 (pl) * 2015-10-26 2024-03-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nowe preparaty kannabinoidów
IL244278A0 (en) * 2016-02-24 2016-07-31 Cannabics Pharmaceuticals Inc An ingredient containing cannabinoids, methods for its preparation and its uses

Also Published As

Publication number Publication date
EP3672610A4 (en) 2021-06-02
AU2018345814A1 (en) 2020-05-14
UY37920A (es) 2019-03-29
CN111225678A (zh) 2020-06-02
EA202090890A1 (ru) 2020-09-03
JP2020536873A (ja) 2020-12-17
EP3672610A1 (en) 2020-07-01
CA3078549A1 (en) 2019-04-11
KR20200065009A (ko) 2020-06-08
US20200254041A1 (en) 2020-08-13
BR112020006841A2 (pt) 2020-10-06
CL2020000909A1 (es) 2020-09-11
WO2019071213A1 (en) 2019-04-11
IL273366A (en) 2020-05-31
MX2020003573A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
AR113749A1 (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2009000600A1 (es) Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
UY37011A (es) Formulaciones líquidas que contienen fungicida
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2016002224A1 (es) Método de obtención de un recubrimiento inorgánico para partículas a base de nitrato de amonio.
CL2017002111A1 (es) Composición ácida a base de leonardita y aminoácidos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2016001375A1 (es) Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo.
CO2021001057A2 (es) Composición y método para el ahorro de opioides
AR064254A1 (es) Maiz extraido con solvente
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
CO2020006257A2 (es) Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria
CO2019003424A2 (es) Extracto de planta impregnado de alulosa y método de preparación para el mismo
CR20160432A (es) Inhibidores de las vías de señalización de wnt
CL2018001017A1 (es) Conservación de vitaminas hidrosolubles.
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
AR053907A1 (es) Producto de consumo que comprende un sistema conservante natural y un metodo para producirlo
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer

Legal Events

Date Code Title Description
FB Suspension of granting procedure